Instructions for Credit — There is no fee for this activity. To receive credit for this CE activity, participants must enroll in this course, review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation/application for credit. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for up to 1.25 continuing education credits. Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or email@example.com.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
Target Audience — Nurse practitioners, nurses and oncology social workers at all levels involved in the care of patients with hematologic malignancies.
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the various types and subtypes of Hodgkin lymphoma (HL)|
|•||Identify tests used to diagnose disease and monitor treatment of HL|
|•||Explain the overarching goals of treatment for the subtypes of HL|
|•||Explain approved and emerging treatment options for HL, including stem cell transplantation, and the role of clinical trials|
|•||Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments for HL|
Provider — This activity is provided by The Leukemia & Lymphoma Society.
Continuing Education for Nurse Practitioners, Nurses, and Social Workers
Nurse Practitioner Credit Designation
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 1.0 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19083830. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.25 continuing education contact hours through the California Board of Registered Nursing.
Social Worker Designation
The Leukemia & Lymphoma Society (LLS)Provider Number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/17-12/14/2020. Social workers completing this course receive 1.25 continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.25 CE clinical contact hours for this activity.
For questions, grievances, or assistance with special needs (physical,. dietary, etc.) please contact us at infocenter@LLS.org.
Disclosure of Conflicts of Interest — All faculty participating in continuing education activities by The Leukemia & Lymphoma Society are expected to disclose to activity participants any significant financial interest or other relationships with the manufacturer(s) of any commercial product(s) discussed in their presentations. The faculty are also expected to disclose any unlabeled or investigational uses of any product(s) discussed in their presentations.
Matthew Matasar, MD, has disclosed he is a Consultant and/or on the Advisory Board for: Bayer, Daiichi Sankyo, Genentech, Juno Therapeutics, Merck, Roche, Rocket Medical, Seattle Genetics, and Teva. He has done Research Funding for: Bayer, Genentech, GlaxoSmithKline, Janssen, Pharmacyclics, Roche, Rocket Medical, and Seattle Genetics.
Timothy Peterson, PharmD, BCOP, has nothing to disclose.
Susan J. McCall, MSN, ANP-BC, AOCNP® is on the Advisory Board for AstraZeneca.
Content Expert Reviewer Disclosure
Tara Duggan, MSN, RN, FNP-BC, OCN®, Content Expert Reviewer, has nothing to disclose.
Disclaimer — The information provided in this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
|Estimated time to complete activity: 1.25 hour|
|Date of initial release: August 9, 2019|
|Valid for CE credit through: August 31, 2020|
Matthew Matasar, MD is a board-certified Medical Oncologist/ Hematologist, who received his undergraduate and medical degrees from Harvard University. His internal medicine training was completed at Columbia Presbyterian, where he earned a Master’s in biostatistics, while serving as Chief Resident. His fellowship training was in medical oncology at Memorial Sloan Kettering Cancer Center, where he subsequently joined faculty on the Lymphoma and Adult BMT services. Dr. Matasar is also the Director of the Lymphoma Survivorship Clinic, where he focuses on the management of long-term survivors of Hodgkin and non-Hodkgin lymphoma. As a member of the lymphoma and BMT services, his research is aimed to explore the management of aggressive lymphomas, focusing on improving outcomes in relapsed but curable patients using novel therapy and stem cell transplantation techniques. His primary research interest is in developing a research program to better understand the optimal care of lymphoma survivors, focusing on reducing the risk and improving the management of late effects of chemotherapy and radiation therapy. He is the Regional Care Network Medical Site Director at MSK Bergen, directing a team of expert medical oncologists in the delivery of cutting-edge care to patients at our outpatient center in Montvale, New Jersey.
Timothy Peterson, PharmD, BCOP, is a Clinical Pharmacy Specialist at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, New York. Dr. Peterson’s areas of focus include multiple myeloma and lymphoma, primarily within the outpatient setting. Dr. Peterson graduated from the University of Minnesota College of Pharmacy before completing a pharmacy practice residency at the University of Iowa Hospitals and Clinics and a second-year oncology residency at MSKCC. He is a Board Certified Oncology Pharmacist (BCOP) and serves as a preceptor for the oncology pharmacy residents at MSKCC.
Susan J. McCall, MSN, ANP-BC, AOCNP®, is Clinical Trials Nurse Practitioner, Lymphoma Service at Memorial Sloan Kettering Cancer Center in New York, NY. I earned my nursing degree at the University of Pennsylvania in Philadelphia, PA. When I began my practice as an NP, I collaborated with lymphoma physicians caring for patients with lymphoma, many of which had Hodgkin lymphoma. In my clinical trials position, I care for Hodgkin lymphoma patients enrolled on Phase I, II, and Ill studies. I am also a strong patient advocate. ensuring adherence to ethical practices and providing education and support for patients in my care.
Resources for HCPs
Online & In-person free CME & CE courses: www.LLS.org/CE
Podcast series for healthcare professionals: www.LLS.org/HCPpodcast
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Resources for Patients
Hodgkin lymphoma Specific Resources: www.LLS.org/Hodgkin-lymphoma
Free Information Booklets: www.LLS.org/Booklets
Telephone/Web Education Programs: www.LLS.org/Programs
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
- Financial Assistance
Information Resource Specialists: www.LLS.org/IRC
Assist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSC
Patients & caregivers work one-on-one with clinical trial specialists who are registered nurses with expertise in blood cancers. RNs will personally assist through the clinical trial process, providing an additional resource to your HCP team.
- Phone: (800) 955-4572, M-F, 9 am to 9 pm ET
- Email: infocenter@LLS.org
Live chat: www.LLS.org/InformationSpecialists